

References

References

A

- **Abenzoza P, Lillemoe T:** CD34 and factor XIIIa in the differential diagnosis of dermatofibroma, a dermatofibrosarcoma protuberans. *Am J Dermatopathol* 1993, 15:429-434.
- **Allgayer H, Babic R, Grutzner KU et al:** Tumor-associated protease inhibitors in gastric cancer: analysis of prognostic impact and individual risk protease patterns. *Clin Exp Metastasis* 1998;16:62-73.
- **Alvanja MCR, Brown CC, Swanson, et al:** saturated fat intake and risk of lung cancer among non-smoking women in Missouri. *J Natl Cancer Inst* 1993; 85:1906.
- **Amos. CL, Xu W, Spitz MR:** is there a genetic basis for lung cancer susceptibility? *Recent Results Cancer Res* 1999; 151: 3.
- **Antonangelo L, Bernardi C, Capelozzi V et al:** morphoetric evaluation of AgNOR is useful in predicting long term survival in Sq. C.C. *Chest* 1997, volume 111, 110-114.
- **Arteaga CL, Winnier AR, Poirier MC et al:** p185 c-erbB-2 signaling enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug induced DNA repair, *Cancer Res* 1994; 54: 3758-3765.
- **Athanasiou A, Gargoulis VG, Zacharatos VG, et al:** c-mos immunoreactivity is an indicator of good prognosis in lung cancer. *Histopathology* 2000, 37: 45-54.

- **Attanos RL, Papagiannis A, Suttinont P et al:** pulmonary giant cell carcinoma: pathological entity or morphological phenotype? *Histopatholgy* 1998, 32:225-231.
- **Aziza J, Mazerolles C, Selves J et al:** Comparison of reactivities of monoclonal antibodies QBEND1 (CD34) and BNH9 in vascular tumors. *Appl Immunohistochem* 1993, 1:51-57.

B

- **Baldus se, Hennecken JK, Spiecker DB, et al:** expression of MMP-2 is associated with progression and lymph node metastasis of gastric carcinoma. *Histopathology* 2001; 39: 597-602.
- **Barbacid M:** *ras* genes. *Ann Rev Bioch* 56:779, 1987.
- **Berho M, Moran MN, Suster S:** Malignant mixed epithelial and mesenchymal neoplasms of the lung. *semin Diagn Pathol* 1995, 12:123-139.
- **Beru KA, Quinlan TR, Moulton G, et al:** Comaparitive proliferative and histopathologic changes in rate lung after inhalation of crysotile or crocidolite asbestos. *Toxicol Appl Pharmacol* 1996; 137:67.
- **Birgitti V, Offerson, Per Pferiffer et al:** Pattern of angiogenesis in non small cell lung carcinoma. *Cancer* 2001; 91: 1500-9.
- **Blackburn EH.** Structure and function of telomeres. *Nature* 1991; 350: 569-573.
- **Boffetta P, Agudo A, Ahrens W, et al:** multicenter case-control study of exposure to environmental tobacco smoke and lung cancer in Europe. *J Natl Cancer Inst* 1998; 90:1440.

References

- **Bongiorno PF, Whyte RI, Lesser EJ, et al:** alternations of the *k-ras*, *p53*, and *erbB-2/neu* in human lung adenocarcinomas. *J Thorac Cardiovasc surg* 107:590, 1994.
- **Bonomi, Phillip:** matrix metalloproteinases and matrix metalloproteinases inhibitors in lung cancer. *Semin-Oncol* 2002; 29(4): 78-86.
- **Borzio M:** Hepatocyte proliferation rate is a powerful parameter for predicting. *Molecular Pathology* 1998; 51: 96-101.
- **Bosari S, Mongeghini L, Graziani D et al:** Bcl-2 oncoprotein in colorectal hyperplastic polyps, adenomas and Adenocarcinoma. *Hum Pathol* 1995; 26:534-540.
- **Brambilla E, Moro D, Veale D, et al:** basal cell (basaloid) carcinoma of the lung. *Am J Surg Pathol* 23: 993-998, 1992.
- **Brambilla E, Gazzeri S, Moro D, et al:** immunohistochemical study of p53 in human lung cancer. *Am J Path* 143:199, 1993.
- **Bramhall SR, Stamp GWH, Dunn J et al:** Expression of collagenase (MMP-2), Stromelysin (MMP-3) and tissue inhibitor of metalloproteinase (TIMP1) in pancreatic and ampullary disease. *British J of Cancer* 1996; 73L972-978.
- **Brennan J, O'Connor T, Makuch RW et al:** myc family DNA amplification in 107 tumors and tumor cell lines from patients with small cell lung cancer treated with different combination chemotherapy agents. *Cancer Res* 1991; 51: 1708-1712.
- **Brody AR.** Asbestos-induced lung disease. *Environ Health Prospect* 1993; 137:67.
- **Brooks PC, Stromblad S, Sanders LC et al:** Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin. *Cell* 1996; 85:683-693.

- **Brown PD, Bloxodge RE, Sturart NSA et al:** Association between expression of 72kda gelatinase and tumor spread in non-small cell lung carcinoma. *J Natl Cancer Inst* 1993; 85: 574-8.
- **Brownson RC, Alavanja MC, Hook ET, et al:** passive smoking and lung cancer in non-smoking women. *Am J Public Health* 1992; 82:1525.
- **Brundage D, Davidson JR, Mackillop W, et al:** Using a treatment-trade off methods to elicit preferences for the treatment of locally advanced non-small lung cancer. *Med Decis Making* 18:256-67, 1998.
- **Burke E, Khan A, Freedman AN, et al:** allelic deletion analysis of FHIT gene predicts poor survival in non-small cell lung cancer. *Cancer Res* 58:2533, 1998.
- **Burnhill RL, Fandrey K, Levy MA et al:** Angiogenesis and tumor progression of melanoma: quantitation of vascularity in melanocytin nevi and cutaneous melanoma. *Lab Invest* 1992; 67: 331-337.
- **Busam KJ, Berwick M, Blessing K et al:** Tumor vascularity is not a prognostic factor for malignant melanoma of the skin. *Am J Pathol* 1995, 147: 1047-1056.
- **Butler AE, Colby TV, Weiss LM, et al:** Lympho-epithelioma like cancer of the lung. *Am J Surge Pathol* 1989; 13: 629-632.

C

- **Cagle PT, el-Naggar AK, Xu Hj, et al:** differential neuroendocrine tumors of the lung.
- **Campbell F, Bogommoletz WV, Williams GT:** Tumors of lung. In *Diagnostic histopathology of tumors*. 2nd ed. London, Edinburgh, New York, Philadelphia, ST Louis: Churchill Livingstone, 2000.

- **Capewell S, Sankaran R, Lamb D, et al:** Lung cancer in life-long nons-mokers. Edinbergh Lung Cancer Group. *Thorax* 46; 1187, 1990.
- **Caporaso N, Goldstein A.** Cancer genes: single and susceptibility: exposing the difference. *Pharmacogenet* 1995; 5; 59.
- **Carbone D:** The biology of the lung cancer. *Semin Oncol* 1997; 24: 388-401.
- **Catherine M, Rachel A, Cooper A, et al:** Tumor vascularity: a histological measure of angiogenesis and hypoxia. *Cancer Res* 2001; 61:2907-2910.
- **Cavenee WK, Koufos A, Hasen MF:** Receive mutant genes predisposing to human cancer. *Mutant Res* 1986; 168:3.
- **Chambers AF, Matrisian LM:** Changing views of the role of matrix metalloproteinase in metastasis. *J Natl Cancer Inst* 1997; 89:1260-70.
- **Chambers AF, Hill RP:** Tumor progression and metastasis. In: *The Basic Science of Oncology, 3rd edn* (Tannok IF, Hill RP, eds). McGraw-Hill, New York, 1998: 219-39.
- **Chandrachud LM, Pendleton N, Chisholm DM, et al:** Relationship between vascularity, age and survival in non-small cell lung cancer. *British J of Cancer* 1997; 76(10)1367-1375.
- **Chappard D:** Increased nucleolar organizer regions in osteoclast nuclei. *Bone* 1998; 22: 45-49.
- **Charlotte F, L, Hermine A, Martin N et al:** Immunohistochemical detection of Bcl-2 protein in normal and pathological human liver. *Am J Pathol* 1994; 144: 460-465.
- **Charloux A, Quoix E, Wolkove N, et al.** The increasing incidence of lung Adenocarcinoma: reality or artifact. A review of

- the epidemiology of lung Adenocarcinoma. *Int J Epidemiol* 1997; 26:14.
- **Cheng Y, Poules NE, Lung ML, et al:** Functional evidence of nasopharyngeal carcinoma tumor suppressor gene that apps at chromosome 3p21.3. *Proc Natl Acad Sci USA* 95:3042, 1998.
 - **Chiba A, Takahashi T, Kuroishi T, et al:** Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. *oncogene* 6:1603, 1990.
 - **Chiba W, Sawai S, Ikeda S et al:** DNA content analysis and detection of c-myc and p53 products using flow cytometry in resected lung cancer cases. *Gan To Kagaku Ryoho* 1994; 21: 108-116.
 - **Chin L, Jra H, Wing Y et al:** AgNOR in lung cancer correlation with DNA ploidy and degree of differentiation. *Analyt Quant Cytol Histol* 1997; 19:271-276.
 - **Cho JY, Kim, JH, Lee YH, et al:** Correlation between k-ras gene mutation and prognosis of patients with non-small cell lung cancer. *Cancer* 79:462, 1997.
 - **Chollat-Traquet C:** Women and Tobacco. World Health Organization: Geneva, 1992.
 - **Chung GT, Sundaresan V, Hasleton P, et al:** Sequential molecular genetic changes in lung cancer development. *Oncogene* 11; 2591, 1995.
 - **Codon-Cardo C, Wartinger D, Petrylak D et al:** Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. *J Natl Cancer Instit* 1992; 84: 1251-1256.
 - **Colby TV, Koss N, Travis WD:** Tumors of Lower Respiratory Tract, Third Series, Fascicle 13, Atlas of Tumor Pathology. Armed Forces Institute of Pathology: Washington, DC, 1995.

- **Cook RM, Miller YE, Bunn PA et al:** Small cell lung cancer: etiology, biology, clinical features, staging and treatment. *Curr Prob Cancer* 1993; 17: 69-141.
- **Cooper CA, Carby FA, Bubb VJ, et al:** The pattern of k-ras mutation in pulmonary Adenocarcinoma defies a new pathway in development of human lung. *J Pathol* 181:401, 1997.
- **Corrin B:** Neuroendocrine neoplasms of the lung. *Curr Diagn Pathol* 1997; 4:239-50.
- **Cotran RS, Kumar V, Collins T.** The respiratory system. In *Robbins pathologic basis of disease*. 6th ed. Philadelphia, London, Tronto, Montreal: WB.Saunders company: 720-755, 1999.
- **Coussens L, Yang TL, Liao YC et al:** Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogenes. *Science* 1985; 230: 1132-1139.
- **Creystal RG, Brantly ML, Hubbard RC, et al:** The alpha antitrypsin gene its uses. *Clinical-consequences strategies for therapy.* *Hest* 1989; 95:196.
- **Crocker J, Nar P:** Nucleolar organizer regions in lymphomas. *Journal of Pathology* 1990.

D

- **Darby S, Whitley E, Silcocks P, et al:** Risk of lung cancer associated residential radon exposure in south-west England: a case control study. *Br J Cancer* 1998; 78:394.
- **Davies B, Miles DW, Happerfield LC et al:** Activity of type VI collagenases in benign and malignant breast disease. *Br J Cancer* 1993; 67: 1126-1131.

- **Davies B, Waxman J, Wasen H et al:** Levels of matrix metalloproteinases in bladder cancer correlate with tumor grade and invasion. *Cancer Res* 1993; 53: 5365-9.
- **De Fusco PA, Frytak S, Dahl RJ, et al;** Cytogenetic changes in 11 small cell carcinoma of the lung. *Mayo Clinic proc* 64:168, 1989.
- **De Gregorio L, Manenti G, Incarbone M, et al:** Prognostic value of loss of heterozygosity and KRAS2 mutations in lung Adenocarcinoma. *Int J Cancer* 79:269, 1998.
- **De Jong JS, Van Diehl and Baak JPA:** Heterogeneity and reproducibility of microvessel counts in breast cancer. *Lab Invest* 1995, 73: 922-926.
- **De Varies J, Kate J, Bosman F:** P21ras in carcinogenesis. *Pathol Res Pract* 1996; 192:658-68.
- **De Vos S, Miller CW, Takeuchi S, et al:** Alternations of CDKN2 (P16) in non-small lung cancer. *Genes Chromosomes Cancer* 14:164, 1995.
- **Dean DC, Weintrub SJ, Holtzman MJ et al:** A molecular switch between lung development and cancer: Is the tumor suppressor Rb turned on during bronchial epithelial cell differentiation and turned off in small cell lung cancer? *Am J Respir Cell Mol Biol* 1994; 11:249-250.
- **Denekamp J, Hobson B:** Endothelial cell proliferation in experimental tumors. *Br J Cancer* 1982; 46: 711-720.
- **Dennisenko MF, Pao A, Tang M, et al:** Preferential formation of benzo (a) pyrene adducts at lung cancer mutational hotspots in p53. *Science* 274:430, 1996.

- **Dockery DW, Trichopoulos D:** Risk of lung cancer from environmental exposures to tobacco smoke. *Cancer causes control* 1997; 8:333-45.
- **Dolecetti R, Doglioni C, Maestro R et al:** p53 expression is an early event in the development of squamous cell carcinoma of the larynx: genetic and prognostic implications. *Int J Cancer* 1992; 52: 178-82.
- **Donghui L, Pervez F, Firozi, et al:** Sensitivity to DNA damage induced by benzo (a) pyrene diol epoxide and risk of lung cancer: a case control analysis. *Cancer Res* 2001; 15: 1445-1450.
- **Druck T, Hadaczek P, Fu TB, et al:** Structure and expression of the human FHIT gene in normal and tumor cells. *Cancer Res* 57:504, 1997.
- **Dunstan S, Powe DG, Wilkinson M et al:** The tumor stroma of oral squamous cell carcinomas showed increased vascularity compared with adjacent host tissue. *Br J Cancer* 1997; 75: 559-565.

E

- **Easton D, Peto J.** The contribution of inherited predisposition to cancer incidence. *Cancer Surveys* 1990; 3:396.
- **Eduardo P, Antonangelo L, Fabiola D et al:** Useful prognostic panel markers to express the biological tumor status in resected lung Adenocarcinoma. *Japanese Journal of Clinical Oncology* 2000, 30:478-486.
- **Eiseman RN:** Myc, Max and Mad: a regulatory network. *Adv Oncol* 1994; 10: 3-6.
- **El-Diery W, Tokino T, Velculescu V et al:** WAF1, a potential mediator of p53 tumor suppression. *Cell* 1993; 75: 817-25.

- **El-Naggar AK, Balance W, Abdul-Kari FW et al:** Typical and atypical bronchopulmonary carcinoids: a clinicopathologic and flow cytometric study. *Am J Clin Pathol* 1991, 95: 828-834.
- **El-Sabban ME, Paul BU:** Adhesion-mediated gap junctional communication between lung metastatic cancer cells and endothelium. *Invasion Metastasis* 1994; 14: 164-76.
- **El.Bolkainy N:** Topographic pathology of cancer (19-23), 2000.

F

- **Farrow S, Brown R:** New members of bcl-2 family and their protein partners. *Cur Opin Genet Dev* 1996; 6:45-9.
- **Fickler MJ, Civin CI, Sutherland DR et al:** Activated protein kinase C directly phosphorylates the CD34 antigen on hematopoietic cells. *J Biol Chem* 1990, 265: 11056-11061.
- **Fidler IJ:** Molecular biology of cancer: Invasion and metastasis. In: *Cancer: Principles and Practice of Oncology*, 5th ed (De Vita, VT, Hellman S, Rosenberg SA, eds). Lippincott-Raven: Philadelphia, 1997:135-52.
- **Fishback NF, Travis WD, Moran CA et al:** Pleomorphic (spindle/giant cell) carcinoma of the lung cancer 1994, 73:2936-2945.
- **Fishel R, Kolodner R, Liskay M:** Mutations in the mismatch repair gene homologue Hmlh1s associated with hereditary non polyposis colon cancer. *Nature* 1994; 368: 258-261.
- **Folkman J:** Tumor angiogenesis: a possible control point in tumor growth. *Ann Intern Med* 1995; 82: 96-100.
- **Folkman J:** Clinical application of research on angiogenesis. *N Engl J Med* 1995; 333: 1757-63.

References

- **Fong K, Zimmerman PV, Smith PJ et al:** Microsatellite instability and other molecular abnormalities in non-small cell lung cancer. *Cancer Res* 1994; 54: 2084-2087.
- **Fong KM, Biesterveld EJ, Virmani A, et al:** FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and pre-neoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations. *Cancer Res* 57:2256, 1997.
- **Fontanini G, Bigini D, Viganti S, et al:** Microvessel count predicts metastatic disease and survival in non-small cell lung cancer. *Journal of Pathology* 1995; 177:57-63.
- **Fontanini G, Vignati S, Bigin D et al:** Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small cell lung cancer. *Br J Cancer* 1995; 71:1003-1007.
- **Fontanini G, Vignati s, Lucchi M et al:** Neoangiogenesis and p53 protein in lung cancer: their prognostic role and their relation with vascular endothelial growth factor (VEGF) expression. *British J of Cancer* 1996, 75(9): 1295-1301.
- **Fontanini G, Viganti S, Mussi A, et al:** Angiogenesis as a prognostic indicator of survival in non-small cell lung cancer: a prospective study. *J Natl Cancer Inst*, 1997; 89: 881-886.
- **Fontham ETH, Correa P, Reynolds, et al:** Environmental tobacco smoke and lung cancer in non-smoking women. A multicenter study.
- **Francoise B, Galateau-Salle, Rafafel, et al:** Matrix metalloproteinases and tissue inhibitors of metalloproteinases in bronchial squamous preinvasive lesions. *Journal of pathology* 2000; 296-305.

- **Fraser GE, Beeson WL, Phillips RL, et al:** Diet and lung cancer in California Seventh-Day Adventists. *Am J Epidemiology* 1991; 133:683?
- **Friend S, Bernards R, Rogliji S, et al:** A human DNA segment with prosperities of the gene that predisposes to retinoblastoma and osteosarcoma. *Nature* 323:643, 1986.

G

- **Garbisa S, Scagliotti G, Masiero L et al:** Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy. *Cancer Res* 1992, 52: 4548-4549.
- **Garfinkel L, Silverberg E:** Lung cancer and smoking trends in the United States over the past 25 years. *CA* 41: 137-145, 1991.
- **Garshik E, Schenker MB, Munoz A, et al:** A retrospective cohort study of lung cancer and diesel exhaust exposure in railroad workers. *Am Rev Respir Dis* 1988; 137:820?
- **Gasparini G, Weidner N, Maluta S et al:** Intratumoral microvessel density and p53 protein: correlation with metastasis in head and neck squamous cell carcinoma. *Int J Cancer* 1993; 55: 739-744.
- **Gazzeri S, Della Valle V, Chaussada L, et al:** The human p19ARF protein encoded by the beta transcript of the p16INK4a gene is frequently lost in small cell lung cancer. *Cancer Res* 58:3926, 1998.
- **Gazzeri S, Gouyer V, Vourch, et al:** Mechanisms of p16INK4A inactivation in non-small cell lung cancers. *Oncogene* 16:497, 1998.

- **Fraser GE, Beeson WL, Phillips RL, et al:** Diet and lung cancer in California Seventh-Day Adventists. *Am J Epidemiology* 1991; 133:683?
- **Friend S, Bernards R, Rogliji S, et al:** A human DNA segment with prosperities of the gene that predisposes to retinoblastoma and osteosarcoma. *Nature* 323:643, 1986.

G

- **Garbisa S, Scagliotti G, Masiero L et al:** Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy. *Cancer Res* 1992, 52: 4548-4549.
- **Garfinkel L, Silverberg E:** Lung cancer and smoking trends in the United States over the past 25 years. *CA* 41: 137-145, 1991.
- **Garshik E, Schenker MB, Munoz A, et al:** A retrospective cohort study of lung cancer and diesel exhaust exposure in railroad workers. *Am Rev Respir Dis* 1988; 137:820?
- **Gasparini G, Weidner N, Maluta S et al:** Intratumoral microvessel density and p53 protein: correlation with metastasis in head and neck squamous cell carcinoma. *Int J Cancer* 1993; 55: 739-744.
- **Gazzeri S, Della Valle V, Chaussada L, et al:** The human p19ARF protein encoded by the beta transcript of the p16INK4a gene is frequently lost in small cell lung cancer. *Cancer Res* 58:3926, 1998.
- **Gazzeri S, Gouyer V, Vourch, et al:** Mechanisms of p16INK4A inactivation in non-small cell lung cancers. *Oncogene* 16:497, 1998.

- **Giaccone G:** Oncogenes and antioncogenes in lung tumorigenesis. *Chest* 1996; 109:130S-4S.
- **Giatromanolaki A, Koukourakis M, O'Byrne K, et al:** Prognostic value angiogenesis in operable non-small cell lung cancer. *Journal of pathology* 1996; 179:80-88.
- **Giatromanolaki A, Koukourakis MI, Colmey M et al:** Platelet derived endothelial cell growth factor expression in lung cancer. *Pathol* 1997; 181: 196-199.
- **Giatromanolaki A, Koukourakis MI, Kaklamanis L et al:** Focal thymidine phosphorylase expression associates with local neoangiogenesis and CD31 positive lymphocytic aggregation in non small cell lung cancer. *Anticancer Res* 1998; 18: 71-76.
- **Giatromanolaki A, Koukourakis MI, Kakolyris et al:** Vascular endothelial growth factor, wild type p53 and angiogenesis in early operable non small cell lung cancer. *Clin Cancer Res* 1998; 4: 3017-3024.
- **Giri JF, Nottingham J, Lawry SA, et al:** Silver binding nucleolar organizer regions in benign and malignant breast lesions: correlation with ploidy and growth phase by DNA flow cytometry. *Journal of pathology* 1989, vol 157:307-313.
- **Gouyer V, Gazzeri S, Brambilla E et al:** Loss of heterozygosity at the RB locus correlates with loss of RB protein in primary neuroendocrine tumors of the lung. *Int J Cancer* 1994; 58: 818-824.
- **Gouyer V, Gazzeri S, Bolon I, et al:** Mechanisms of retinoblastoma gene inactivation in the spectrum of neuroendocrine lung tumors. *Am J Respir Cell Mol Biol* 18:188, 1998.
- **Gray ST, Yun K, Mootori T et al:** Interstitial collagenase gene expression in colonic neoplasm. *Am J Pathol* 1993, 143:663-671.

- **Greaves MF, Brown J, Molgaard HV et al:** Molecular features of CD34: A hemopoietic progenitor cell-associated molecule. *Leukemia* 1992,6: 31-36.
- **Greenlee RT, Murray T, Bolden S, et al:** Cancer statistics, 2000. *CA Cancer J Clin* 50:7, 2000.
- **Gritz ER:** Lung cancer, now, more than ever, a feminist issue *CA*. 43: 197-199, 1993.
- **Gunduz N:** Cytokinetics of tumor and endothelial cells and vascularization of lung metastasis in C3H/He mice. *Cell Tissue Kinet* 1981; 14: 343-363.
- **Gyther SA, Barski P, Batley SJ, et al:** aberrant splicing of the TSG101 and FHIT genes occurs frequently in multiple malignancies and in normal tissues and mimic alternations previously described in tumors. *Oncogene* 15:2119, 1997.

H

- **Haber DA:** Telomeres, cancer, and immortality. *N Engl J Med* 1995; 332: 955-956.
- **Hackshaw AK, Law MR, Wald NJ, et al:** The accumulated evidence of lung cancer and environmental tobacco smoke. *Br Med J* 1997; 315:980.
- **Hainaut P, Hernandez T, Robinson A, et al:** IARC database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualization tools. *Nucleic Acids Res* 26:205, 1998.
- **Hajitou A, Sounni NE, Devy L, et al:** Down regulation of vascular endothelial growth by tissue inhibitor of metalloproteinase-2: Effect on in vivo mammary tumor growth and angiogenesis. *Cancer Res* 2001; 61:3450-3457.

- **Halpern MT, Gillespie BW, Warner KE, et al.** Patterns of absolute risk of lung cancer mortality in former smokers. *J Natl Cancer Inst* 1993; 85:457.
- **Hamada K, Kohno T, Kawanishi M, et al:** Association of CDKN2A (p16)/CDKN2B (p15) alternations and homozygous chromosome arm 9p deletions in human lung carcinoma. *Genes Chromosomes Cancer* 22:232, 1998.
- **Hamdy FC, Fadlon D, Cottam D et al:** Localization of messenger RNA for MW 72,000 and 92,000 type IV collagenases in human skin cancers by in situ hybridization. *Cancer Res* 1994; 52: 1336-41.
- **Hammond EC, Garfinkel L, Seidman H, et al:** Some recent findings concerning cigarette smoking. In; *Origins of Human Cancer. Book A: Incidence of Cancer in Humans* (Hiatt HH, Watson JD, Winsten JA, eds). Cold Spring Harbor Laboratory: New York, 1977:101-12.
- **Hanson CA, Ross CW, Schnizer B:** Anti-CD34 immunoperoxidase staining in paraffin sections of acute leukemia: comparison with flow cytometric immunophenotyping. *Hum Pathol* 1992, 23: 26-32.
- **Haque A K 1991 Pathology of carcinoma of the lung:** An update on current concepts. *Thorac Imaging* 7: 9-20
- **Harpole DH, Herndon JE, Wolfe WG et al:** A prognostic model of recurrence and death in stage 1 non small cell lung cancer utilizing presentation, histopathology and oncoprotein expression. *Cancer Res* 1995; 55: 51-56.
- **Haung CL, Taki T, Adachi M, et al:** Mutations of p53 and k-ras genes as prognostic factors of non-small lung cancer. *Int J Oncol* 12:553, 1998.

- **Hirvonen A.** Polymorphisms of xenobiotic- metabolizing enzymes and susceptibility of cancer. *Environ Health Prespect* 1999; 107(suppl 1):37.
- **Hiyama k, Hiyama E, Ishioka S et al:** Telomerase activity in small cell and non-small cell lung cancers. *J Natl Cancer Inst* 1995; 87: 895-902.
- **Hockenbery D, Nunez G, Milliman C et al:** Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. *Nature* 1990; 348: 334-336.
- **Hoffmann D, Hoffmann I:** The changing cigarette, 1950-1995. *J Toxicol Environ Health* 1997; 50:307-64.
- **Hollingsworth HK, Kohn EC, Steinberg SM et al:** Tumor angiogenesis in advanced stages of ovarian carcinoma. *Am J Pathol* 1995; 147: 33-41.
- **Holmgren L, O'Reilly MS, Folkman J:** Dormancy of micrometastasis:balanced proliferation and apoptosis in the presence of angiogenesis suppression. *Nature Med* 1995; 1: 149-53.
- **Hoyhtya M, Fridman R, Komarek D et al:** Immunohistochemical localization of matrix metalloproteinase-2 and its specific inhibitor TIMP-2 in neoplastic tissues with monoclonal antibodies. *Int J Cancer* 1994: 56:500-505.
- **Hrabec E, Streck M, Nowak, et al:** Activity of type IV collagenases (MMP-2 and MMP-9) in primary pulmonary carcinomas: a quantitative analysis. *J Cancer Res Clin Oncol* 2002; 128(2): 197-204.
- **Hu c, Chein SL:** The cytoplasmic domain of stem cell antigen CD34 is essential for cytoadhesion signaling but not sufficient for proliferation signaling. *Blood* 1998, 91: 1152-1162.

- **Hung J, Kishimoto Y, Sugio K, et al:** Allele-specific chromosome 3p deletions occur at an early stage in the pathogenesis of lung carcinoma. *JAMA* 273:558, 1995.
- **Husgafvel-Pursiainen K, Hakman P, Ridanpaa M, et al:** k-ras mutations in human Adenocarcinoma of the lung: association with smoking and occupational exposure to asbestos. *Int J Cancer* 53; 250, 1993.

I

- **IARC:** Diesel and gasoline exhausts and some nitrosamines. In evaluation of carcinogenic risk of chemicals to man. Vol.46, Lyon: International Agency for Research on Cancer. Improvement of breast cancer prognostication using cell kinetic. *Virchows Archiv: an international Journal of Pathology* 2001; 5: 478-484.
- **International Agency for Research on Cancer (IARC).** *Tobacco smoking*. IARC Monographs on the evaluation of carcinogenic risk of chemicals to humans. Vol. 38, Lyon: IARC, 1986.
- **Ionov Y, Peinado MA, Malkhosnyan S et al:** Ubiquitous mutations in simple repeated sequences reveal a new mechanism for carcinogenesis. *Nature* 1993; 363: 558-561.
JAMA 1994; 271:1752.

J

- **Jiang SX, Kameya T, Shoji M, et al:** Large cell neuroendocrine carcinoma of the lung: a histologic and immunohistochemical study of 22 cases. *Am J Surg Pathol* 1998; 22:526-37.
- **Johnson BE, Brennan JF, Ihda DC et al:** Myc family DNA amplification in tumors and tumor cell lines from patients with small cell lung cancer. *J Natl Cancer Inst Mongor* 1992; 13: 39-43.

- **Johnson RC, Zhu D, Voss HG:** Lung endothelial dipeptidyl peptidase IV is an adhesion molecule for lung metastatic rat breast and prostate carcinoma cells. *J Cell Biol* 1993; 121: 1423-32.
- **Johnson BE:** Biologic and molecular prognostic factors- impact on treatment of patients with non-small cell lung cancer. *Chest* 107:287S- 90S, 1995.

K

- **Kashiwabara K, Oyama T, Sano T, et al:** Correlation between methylation status of the p16/CDKN2 gene and expression of p16 and Rb proteins in primary non-small cell lung cancers. *Int J Cancer* 79:215, 1998.
- **Kawano N, Osawa H, Ito T et al:** Expression of gelatinase A, Tissue inhibitor of Metalloproteinase-2, Matrilysin, and Trypsin (ogen) in Lung Neoplasm. *Human pathology* 1997, vol 28, No.5:613-621.
- **Kayser K, Kayser C, Rahn W, et al:** Carcinoid tumors of the lung: immuno- and legend histochemistry, analysis of integrated optical density, syntactic structure analysis, clinical data, and prognosis of patients treated surgically. *J Surg Oncol* 63:99-106, 1996.
- **Keohavong P, Zhu D, Whiteside TL, et al:** Detection of infrequent and multiple k-ras mutations in human tumors and tumor adjacent tissues. *Anal Bioch* 247:394, 1997.
- **Khuri FR, Lippman SM, Spitz MR, et al:** molecular epidemiology and retinoid chemoprevention of head and neck cancer. *J Natl Cancer Inst* 1997; 89:199.

- **Kim SK, Ro JY, Kemp BL, et al:** Identification of three distinct tumor suppressor loci on the short arm of chromosome 9 in small cell lung cancer. *Cancer Res* 57:400, 1997.
- **Kitagawa Y, Wong F, Lo p, et al:** Over expression of Bcl-2 and mutations of p53 and k-ras in resected human non-small cell lung carcinoma. *Am J Resp Cell Mol Biol* 15:45; 1996.
- **Kok K, Van den Berg A, Veldhuis PM, et al:** A homozygous deletion in a small cell lung cancer cell line involving a 3p21.3 region with a marked instability in yeast artificial chromosome. *Cancer Res* 54:4183, 1994.
- **Kornblau SM, Xu HJ, Giglio A et al:** Clinical implication of decreased retinoblastoma gene expression in acute myelogenous leukemia. *Cancer Res* 1992; 52: 4587-4590.
- **Korsmeyer SJ:** Bcl-2 initiates a new category of oncogenes: regulators of cell death. *Blood*; 1992: 80:879-886.
- **Koss MN, Hochholzer L, Oleary T, et al:** Pulmonary blastomas. *Cancer* 1991, 67:2368-2381.
- **Koss MN, Hochholzer L, Frommelt RA:** Carcinosarcomas of the lung. A clinicopathologic study of 66 cases. *Am J Surg Pathol* 1999, 23:1514-1526.
- **Kossakowaska AE, Huchcroft SA, Urbanski SJ, et al:** Comparative analysis of the expression pattern of metalloproteinase and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary carcinomas and malignant non-Hodgkin's lymphomas in humans. *British J of Cancer* 1996; 73: 1401-1408.
- **Kraden RL, Kirkham SE, Young RH et al:** Pulmonary blastoma with argyrophil cells and lacking the sarcomatous feature

- (pulmonary endodermal tumor resembling fetal lung). *Am J Surg Pathol* 1982; 6: 165-72.
- **Kreuzer M, Kreienbrock L, Gerken M, et al.** Risk factors for lung cancer in young adults. *Am J Epidemiol* 1998; 147:1028.
 - **Kruger S:** cell cycle-dependent AgNOR analysis in invasive breast cancer. *Analytical and Quantitative Cytology and Histology* 2000; 22: 358-363.
 - **Kumaki F, Matsui K, Kawai T, et al:** Expression of matrix metalloproteinases in invasive pulmonary Adenocarcinoma with bronchioloalveolar component and atypical adenomatous hyperplasia. *American J of Pathology* 2001; 159(6): 2125-2135.
 - **Kurasono Y, Ito K, Kameda Y, et al:** Expression of cyclin D1 and retinoblastoma gene protein, and p16 MTS1 protein in atypical adenomatous hyperplasia and Adenocarcinoma of the lung. An immunohistochemical analysis. *Virchow Arch* 432:207, 1998.
 - **Kwiatkowski DJ, Harpole DH, Godleski J et al:** Molecular pathologic substaging in 244 stage I non-small cell lung cancer patients: clinical implications. *J Clin Oncol* 1998; 16: 2468-77.

L

- **Landis SH, Murray T, Bolden S et al:** Cancer Statistics 1998. *CA Cancer J Clin* 1998; 48: 6-29.
- **Lee WH, Bookstein R, Hong F, et al:** Human retinoblastoma susceptibility gene. Cloning, identification, and sequence. *Science* 235: 1394, 1987.
- **Lee JS, Yoon A, Kalapurakal SK, et al:** Expression of p53 oncoprotein in non-small cell lung cancer: A favorable prognostic factor. *J Clin Oncol* 13:1893, 1995.

References

- **Lee YC, Chang DB, Lee JM et al:** Nucleolar organizer regions as a prognostic factor in surgically treated lung cancer patients. *Thorac-Cardiovasc-Surg* 1996 Aug; 44(4):204-7.
- **Lee JS, Jonthan M, Fan YH, et al:** Clonal genetic alternations in the lungs of current and former smokers. *Journal of Natl Cancer Inst* 1997; 89(12): 857- 862.
- **Lee YC, Chern JH, Li WY, et al:** AgNORs in lung cancer, correlation with DNA ploidy and degree of differentiation. *Anal-Quant-Cytol-Histol*, 1997 Jun: 19(3):271-6.
- **Leek RD, Kaklamanis L, Pezzella F et al:** Bcl-2 in normal human breast and carcinoma, association with estrogen receptor positive, epidermal growth factor-negative tumors and in situ cancers. *Br J Cancer* 1994; 69: 135-139.
- **LeMarchand L, Yoshizawa CN, Colonel LN, et al:** Vegetable consumption and lung cancer risk: a population-based case control study in Hawaii. *J Natl Cancer Inst* 1989; 81:1158.
- **Levine AJ, Momand J, Finlay CA, et al:** The p53 tumor suppressor gene. *Nature* 351:453, 1991.
- **Li VW, Folkert RD, Watanab H et al:** Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumors. *Lancet* 1994; 334:82-86.
- **Linnoila RI, Piantadosi S, Ruckdeschel JC:** Impact of neuroendocrine differentiation in non-small cell lung cancer. *Chest* 1994; 106: 367S-371S.
- **Little CD, Nau MM, Carney DN et al:** Amplification and expression of the c-myc oncogenes in human lung cancer cell lines. *Nature* 1983; 306:194-196.

- **Logothetis CJ, Xu HJ, Ro JY et al:** Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. *J Natl Cancer Inst* 1992; 84: 1256-1261.
- **Lohmann D, Putz B, Reich V, et al:** Mutational spectrum of p53 gene in human small cell lung cancer and relation to clinicopathological data. *Am J Path* 142:907, 1993.
- **Ionardo F, Rusch V, Langenfeld J, et al:** Overexpression of cyclin D1 and E is frequent in bronchial preneoplasia and preceded squamous cell carcinoma development. *Cancer Res* 1999; 59: 2470-2476.
- **Lotem J, Sachs L:** Regulation by Bcl-2, C-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compound in differentiation-competent and defective myeloid leukemic cells. *Cell growth differ* 1993; 4: 41-47.
- **Lubin JH, Boice JD Jr.** Lung cancer risk from residential radon: meta-analysis of 8 epidemiologic studies. *J Natl Cancer Inst* 1995; 89:49.

M

- **MacDonald TJ, Korsmeyer SJ:** Progression from lymphoid hyperplasia to high grade malignant lymphoma in mice transgenic for the t (14; 18). *Nature* 1991; 349:254-256.
- **MacLaren R, Kuzu I, Dunnill M, et al:** The relationship of p53 immunostaining to survival in carcinoma of the lung. *Br J Cancer* 66:735, 1993.
- **Magrath I, Litvak J.** Cancer in developing countries: opportunity and challenge. *J Natl Cancer Inst* 1993; 85:862.

- **Majdic O, Stockl L, Pickl WF et al:** Signaling and induction of cytoadhesiveness via the hematopoietic progenitor cell surface molecule CD34. *blood* 1994, 83: 1226-1234.
- **Malkin D, Li FP, Strong LC, et al:** Germ line p53 mutation in a familial syndrome of breast cancer sarcomas and other neoplasms. *Science* 1990; 250:1233.
- **Mannino DM, Ford E, Giovono GA, et al:** Lung cancer deaths in the United States from 1979 to 1992: an analysis using multiple cause mortality data. *Int J Epidemiol* 1998; 27:159-66.
- **Mao L, Lee JS, Kurie JM, et al:** Clonal genetic changes in the lungs of current and former smokers. *J Natl Cancer Inst* 89; 857, 1997.
- **Marchetti A, Doglioni C, Barbareschi M et al:** p21 RNA and protein expression in non-small cell lung cancer: evidence of p53 independent expression and association with tumor differentiation. *Oncogenes* 1996; 12:1319-24.
- **Marchetti A, Pellegrini S, Bertacca G, et al:** FHIT and p53 gene abnormalities in bronchioloalveolar carcinomas. Correlations with clinicopathological data and k-ras mutations. *J Pathol* 184:240, 1998.
- **Marchetti D, Doglioni C, Barbareschi M, et al:** Cyclin D1 and retinoblastoma susceptibility gene alternations in non-small cell lung cancer. *Int J Cancer* 75:187, 1998.
- **Martin L, Green B, Renshaw C et al:** Examining the techniques of angiogenesis assesment in invasive breast cancer. *British Journal of cancer* 1997; 76(8): 11046-1045.
- **Masuya D, Huang CL, Liu D, et al:** The intratumoral expression of vascular endothelial growth factor and interleukin-8 associated

- with angiogenesis in non small cell lung cancer patients. *Cancer* 2001; 92(N 10): 2628-2638.
- **Mayne ST, Janerich DT, Greenwald P, et al:** Dietary beta carotene and lung cancer risk in U.S non-smokers. *J Natl Cancer Inst* 1994;86:33.
 - **McDonald JC, Liddel FDK, Gibbs GW, et al:** Dust exposure and mortality in chrysotile mining, 1910-75. *Br J Indust Med* 1980; 37:11.
 - **McDonnell TJ, Troncoso P, Brisbay SM et al:** Expression of protooncogene Bcl-2 in the prostate and its association with emergence of androgen-dependent prostate cancer. *Cancer Res* 1992; 52:6940-6944.
 - **Mead LJ, Gillespie MT, Hung JY, et al:** Frequent loss of heterozygosity in early non-small cell lung cancers at chromosome 9p21 proximal to the CDKN2a gene. *Int J Cancer* 71:213, 1997.
 - **Meert AP, Paesmans M, Mrtin B et al:** The role of microvessel density on the survival of patients with lung cancer: a systemic review of literature with meta-analysis. *British J of Cancer* 2002, 87: 496-471.
 - **Merlo A, Mabry M, Gabrielson E et al:** Frequent microsatellite instability in primary small cell lung cancer. *Cancer Res* 1994; 54: 2098-2101.
 - **Miganatti P, Rifkin DB:** Biology and biochemistry of proteinases in tumor invasion. *Physiol* 1993; 73: 161-95.
 - **Miki Y, Swenson J, Shattuck-Eidens D, et al:** Isolation of BRCA1, the 17q-linked breast and ovarian cancer susceptibility gene. *Science* 1994; 266:66.

- **Miller CW, Simon K, Aslo A, et al:** p53 mutations in human lung tumors. *Cancer Res* 52:1695, 1992.
- **Mitsudomi T, Steinberg SM, Nau MM, et al:** p53 mutations in non-small cell cancer cell lines and their correlation with the presence of ras mutations and clinical features. *oncogene* 7:171, 1992.
- **Mitsudomi T, Oyama T, Kusano T, et al:** Mutations of p53 as a predictor of poor prognosis in patients with non-small cell lung cancer. *J Natl Cancer Inst* 85:2018, 1993.
- **Mitsudomi T, Yatabe Y, Koshikawa T, et al:** Mutation of the p53 tumor suppressor gene as clonal marker for multiple primary lung cancers. *J Thorac Cardiovasc Surg* 114:354, 1997.
- **Miyashita T, Reed J:** Tumor suppressor P53 is a direct transcriptional activator of human bax gene. *Cell* 1995;80: 293-9.
- **Monig SP, Hennecken JK, Spieker DB et al:** Expression of Matrix Metalloproteinase-2 is associated with progression and lymph node metastasis of gastric carcinoma. *Histopathology* 2001, 39:597-602.
- **Moran CA, Hochholzer L, Fishback NF, et al:** Mucinous (so called colloid) carcinoma of lung. *Mod pathol* 1992, 5:634-638.
- **Moran CA, Suster S, Koss MN 1992:** Acinic cell carcinoma of the lung (Fechner tumor): A clinicopathologic, immunohistochemical and ultrastructural study of 5 cases. *Am J Surg Pathol* 1992, 16:1039-1050.
- **Moran CA, Suster S, Koss MN:** primary adenoid cystic carcinomas of the lung: a clinicopathologic and immunohistochemical study of 16 cases. *Cancer* 1994, 73: 1390-1397.

- **Moran CA:** Mucin rich tumors of the lung. *Adv Anat Path* 1995, 2(5): 299-305.
- **Moran CA:** Primary salivary gland-type tumor of the lung. *Semin Diagn Pathol* 1995, 12: 106-122.
- **Morkov O, Halvorsen OJ, Stangeland L et al:** Quantitation of biological tumor markers (p53-c-yc- Ki-67 and DNA ploidy) by multiparameter flow cytometry in non-small cell lung cancer. *Int J Cancer* 1992; 52: 851-855.
- **Mountain CF:** Revisions in the international system for staging lung cancer. *Chest*, 111:1710-7, 1997.
- **Mumford JL, He XZ, Chapman RS, et al:** Lung cancer and indoor air pollution in Xuan Wei, China. *Science* 1987; 235:217.
- **Muss HB:** Thor AD, Berry AD et al: c-erbB-2 expression and response to adjuvant therapy in women with node positive early breast cancer. *N Engl Med* 1994; 330: 1260-1266.

N

- **Nakachi K, Imai K, Hayashi S, et al:** Genetic susceptibility to squamous cell carcinoma of the lung in relation to cigarette smoking dose. *Cancer Res* 1991; 51:5177.
- **Nakagawa K, Conrad NK, Williams JP, et al:** Mechanisms of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage. *Oncogenes* 11: 1843, 1995.
- **Nakajima M, Chop AM:** Tumor invasion and extracellular matrix degradative enzymes: regulation of activity by organ factors. *Semin Cancer Biol* 1991;2: 115-17.
- **Nakamura H, Ueno H, Yamashita K, et al:** Enhanced production and activation of progelatinase A mediated by membrane type 1

- **Ohmura Y, Aoe M, Andou A, et al:** Telomerase activity and Bcl-2 expression in non-small cell lung cancer. *Clin Cancer Res* 2000; 6: 2980- 2987.
- **Okamoto A, Hussein SP, Hagiwara K, et al:** Mutations in the p16INK4/MTS1/CDKN2, P15INK4B/MTS2, and P18 genes in primary and metastatic lung cancer. *Cancer Res* 55:1448, 1995.
- **Olivarez d, Ulbrigh T, Deirese W et al:** Neovascularization in clinical stage A testicular germ cell tumor: prediction of metastatic disease. *Cancer Res* 1994; 54:2800-2802.
- **Omenn GS, Goodman GE, Thoronquist, et al:** Risk factors for lung cancer and for intervention effects in CARTE, the Beta Carotene and Retinol Efficacy Trial. *J Natl Cancer Inst* 1996; 88:1550.
- **Ooi WL, Eleston RC, Chen VW, et al:** Increased familial risk for lung cancer. *J Natl Cancer Inst* 1986; 76:217.
- **Osann KE.** Lung cancer in women: the importance of smoking, family history of cancer, and medical history of respiratory diseases. *Cancer Res* 1991; 51:4893.
- **Otterson GA, Xiao GH, Geradts J, et al:** Protein expression and functional analysis of FHIT gene in human tumor cells. *J Natl Cancer Inst* 90:426:1998.
- **Oyama T, Mitsudomi T, Mizoue et al:** Proliferating cell nuclear antigen may be superior to argyrophilic nucleolar organizer regions in predicting shortened survival of patients with non-small cell lung cancer. *Surg-Oncol.*1995; 4(2):83-9.

P

- **Paolucci L, Rozengurt E:** Protein kinase D in small cell lung cancer: Rapid activation through protein kinase C. *Cancer Res*

- **Shimad T, Hayes CL, Yamazaki H, et al:** Activation of chemically diverse procarcinogens by human cytochrome P450 1B1. *Cancer Res* 1996; 56:2797.
- **Shimosato Y:** Part II, Lung Tumors. In biopsy interpretation of the lung (Shimosato Y, Miller RR). Raven Press: New York, 1994:199-394.
- **Shimosato:** Pulmonary neoplasms. In: *Diagnostic Surgical Pathology: 3rd edn* (Sternberg SS,ed).Raven Press: New York, 1999.
- **Shridhar V, Siegfried J, Hunt J et al:** Genetic instability of microsatellite sequences in many non-small cell lung cancer. *Cancer Res* 1994; 54: 2322-2326.
- **Sier C, Kubben F, Ganesh S et al:** Tissue levels of matrix metalloproteinase MMP-2 and MMP-9 are related to overall survival of patients with gastric carcinoma. *Br J of Cancer* 1996, 74:413-417.
- **Silver SA, Askin FB:** True papillary carcinoma of the lung. A distinct clinicopathologic entity. *Am J Surg Pathol* 1997; 21:43-51.
- **Simons DL, Satterthwaite AB, Tenen DG et al:** Molecular cloning of cDNA encoding CD34, a sialomucin of human hematopoietic stem cells. *J Immunol* 1992, 148: 267-271.
- **Slebos RJ, Hurban RH, Dalesio O, et al:** Relationship between k-ras oncogene activation and smoking in Adenocarcinoma of the human lung. *J Natl Cancer Inst* 83:1024, 1991.
- **Slebos RJC, Rodenhuis S:** The *RAS* gene family in human non-small lung cancer. *J Natl Cancer Inst Monogr* 13:23, 1992.
- **Smith AH, Lopipero PA, Berroga VR.** Meta-analysis of studies of lung cancer among silicosis. *Epidemiology* 1995; 6.

References

- **Sobin LH, Fleming ID:** TNM classification of malignant lung tumors, fifth edition (1997). Union International Contre le Cancer and the American Joint Committee on Cancer. *Cancer* 80:1803-4, 1997.
- **Soini Y, Paako P, Helena A et al:** Genes of laminin B1 chain, $\alpha 1$ (IV) chain of type IV collagen, and 72 kd type IV collagenase are mainly expressed by stromal cells of lung carcinoma. *Am J Pathol* 1993, 142:1622-1630.
- **Sommerfeld HJ, Meeker AK, Piatyszek MA et al:** Telomerase activity: a prevalent marker of malignant human prostate tissue. *cancer Res* 1995; 56: 218-222.
- **Soomro I, Patel N, Whister W:** Distribution and estimation of nucleolar organizer regions in various human lung tumors. *Pathol-Res-Pract* 1991 Jan; 187(1):68-72.
- **Sozzi G, Miozzo M, Tagliabue et al:** Cytogenetic abnormalities and overexpression receptors for growth factors in normal bronchial epithelium and tumor samples of lung cancer patients. *Cancer Res* 1991; 51:5811-15.
- **Sozzi G, Miozzo M, Pastorino U, et al:** Genetic evidence for an independent origin of multiple preneoplastic and neoplastic lung lesions. *Cancer Res* 55:135, 1995.
- **Sozzi G, Sard L, De Gregorio L, et al:** Association between cigarette smoking and FHIT gene in lung cancer. *Cancer Res* 57:2121, 1997.
- **Spink DC Spink PC, Cao JK, et al:** Differential expression of CYP1A1 and CYP1A2 in human breast epithelial cells and breast tumor cells. *Carcinogenesis* 1998; 19:291.

References

- **Sridhar KS, Bounassi MJ, Raub W et al:** Clinical features of adenosquamous lung carcinoms in 127 patients. *Am Rev Respir Dis* 1990, 142: 19-23.
- **Steinmerz KA, Potter JD, Folsom AR, et al:** Vegetables, fruit and lung cancer in the Iowa Women's Health Study. *Cancer Res* 1993; 53:356.
- **Stellman SD, Garfinkle L.** Lung cancer risk is proportional to cigarette tar yield: evidence from a prospective study. *Prev Med* 1989; 18:518.
- **Stockwell HG, Goldman AL, Lyman GH, et al:** Environmental tobacco smoke and lung cancer risk in nonsmoking women. *J Natl Cancer Inst* 1992; 84:1417.
- **Stoilov I, Akarsu AN, Sarfarazi M, et al:** Identifications of three different truncating mutations in cytochrome P450 1B1 (CYP1B1) as the primary cause of primary congenital glaucoma (Buphthalmos) in families linked to the GLC3A locus on chromosome 2P21. *Human Molec Genet* 1997; 39:626.
- **Streenland K, Loomis D, Shy C, et al:** Review of occupational lung carcinogens. *Am J Indust Med* 1996:29:474.
- **Suda J, Sudo T, Ito M et al:** Two types of murine CD34 Mrna generated by alternative splicing. *Blood* 2992, 79: 2288-2295.
- **Sugimura H, Hamada GS, Suzuki I, et al:** CYP1A1, CYP2E1 polymorphisms and lung cancer, a case control study in Rio de Janeiro, Brazil. *Pharmacogent* 1995; 5:S145.
- **Sugio K, Kishimoto Y, Viramani AK, et al:** K-ras mutations are relatively late events in the pathogenesis of lung carcinomas. *Cancer Res* 54:5811, 1994.

- **Sutherland DR, March JC, Davidson J et al:** Differential sensitivity of CD34 epitopes to cleavage by *Pasteurella hemolytica* glycoprotease: implication for purification of CD34+ progenitor cells. *Expo Hematol* 1992, 20: 590-599.
- **Suzuki H, Takahashi T, Kuroishi T, et al:** p53 mutations in non-small lung cancer in Japan: association between mutations and smoking. *Cancer Res* 52:734, 1992.

T

- **Takagi Y, Osada H, Kuroishi T, et al:** p53 mutations in non-small cell lung cancers occurring in individuals without a past history of active smoking. *Br J Cancer* 77:1568, 1998.
- **Takayama k, Ogata K, Nakanishi Y et al:** Bcl-2 expression as a predictor of chemosensitivities and survival in non-small cell lung cancer. *Cancer J Sci Am* 1996; 2: 213-16.
- **Tal M, Wetzler M, Josefberg Z et al:** Sporadic amplification of HER2/neu protooncogene in Adenocarcinoma of various tissues. *Cancer Res* 1988; 48: 1517-1520.
- **Tanaka N, Ishihara M, Kitagawa M et al:** Cellular commitment to oncogenes-induced transformation or apoptosis is dependent on the transcription factor IRF-1. *Cell* 1994; 77: 829-839.
- **Tanaka H, Fujii Y, Hirabayashi H, et al:** Disruption of RB pathway and cell proliferative activity in non-small lung cancer. *Int J Cancer* 79:111, 1998.
- **Tanaka F, Otaka Y, Yanagihara K, et al:** Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody. *Clin Cancer Res* 2001; vol 7:3410-3415.

- **Tang D, David H, Phillips, et al:** Association between carcinogen-DNA adducts in white blood cells and lung cancer risk in the physicians health study. *Cancer Res* 2001; 61; 6708-6712.
- **Tanigawa N, Amaya H, Matsumura M et al:** Extent of tumor vascularization correlates with prognosis and hematogenous metastasis in gastric carcinoma. *Cancer Res* 1996, 56: 2671-2676.
- **Todd MC, Xiang RH, Garcia DK, et al:** An 80 kb p1 clone from chromosome 3p21.3 suppresses tumor growth in vivo. *Oncogene* 13:2387:1996.
- **Tokuraku M, Sato H, Murakami S, et al:** Activation of the precursor of gelatinase A/72kDa type IV collagenase/MMP-2 in lung carcinomas correlates with the expression of membrane type matrix metalloproteinase (MT-MMP) and with lymph node metastasis. *Int J Cancer* 1995; 64: 355-359.
- **Tomatis L, Air Pollution and Human Cancer:** European School of Oncology Monograph. Springer Verlag: Berlin, 1990.
- **Travis WD, Linnoila R, Tsokos MG:** Neuroendocrine tumors of the lung with proposed criteria for large cell neuroendocrine carcinomas. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. *Am J Surg path* 1991, 16: 529-533.
- **Travis WD, Travis LB, Devesa LS, et al:** Lung cancer. *Cancer* 1995; 75:191-202.
- **Travis WD, Lubin J, Ries L, et al:** United States lung carcinoma incidence trends: declining for most histologic types among males, increasing among females. *Cancer* 77:2464, 1996.
- **Travis WD, Rush W, Flieder DB et al:** Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria of

- atypical carcinoid and its separation from typical carcinoid. *Am J Surg Pathol* 1998, 22: 934-944.
- **Tron VA, Krajewski S, Klein H et al:** Immunohistochemical analysis of Bcl-2 regulation in coetaneous melanoma. *Am J Pathol* 1995; 146: 643-650.
 - **Tsai C, Chang KT, Wu LH et al:** Correlation between intrinsic chemoresistance and HER-2/neu gene expression, p53 mutations, and cell proliferation charecterstics in non small cell lung cancer cell lines. *Cncer Res* 1996; 56: 296-209.
 - **Tsuchiya E, Furuta R, Wada N, et al:** High k-ras mutation rates in goblet-cell type adenocarcinoma of the lungs. *Cancer Res Clin Oncol* 121: 577, 1995.

U

- **U.S Department of Health and Human Services:** The health consequences of chronic smoking: chronic obstructive lung disease. A report of the Surgeon General. U.S Department of Health and Human Services, Office on Smoking and Health. DHHS Pub. No.84-50205, 1984.
- **Uaeger TM, Weidner N, Chew K et al:** Tumor angiogenesis and lymph node metastasis in invasive bladder carcinoma. *J Urol* 1994; 151: 348.
- **Urban T, Ricci S, Lacave R, et al:** Codon 12 ki-ras mutation in non-small cell lung cancer: comparative evaluation in tumoral and non-tumoral lung. *Br J Cancer* 74:1051, 1996.

V

- **Van De Rijn M, Henderkison MR, Rous RV:** CD34: A review: *Appl Immunohistochem* 1994, 21: 71-80.

- **Van Hoef MEHM, Knox WF, Dhesi SS et al:** Assesement of tumor vascularity as a prognostic factor in lymph node negative invasive breast cancer. *Eur J Cancer* 1993, 29A: 1141-1145.
- **Vanderwinden JM, Rumessen JJ, De Laet H et al:** CD34+ cells in human intestine are fibroblastic adjacent to, but distinct from interstitial cells of Cajal. *Lab Invest* 1999, 79:59-65.
- **Vineis P, Bartsch H, Caporaso N, et al:** Genetically base N-acetyltransferase metabolic polymorphism and low level environmental exposure to carcinogens. *Nature* 1994; 369:154.
- **Vineis P, Martone T:** Genetic-environmental interactions and low-level exposure to carcinogens. *Epidemiol* 1995; 6:455.
- **Volm M, Drings P, Wodrich W et al:** Expression of oncoprotein in primary human non-small cell lung cancer and incidence of metastases. *Clin Exp Metastasis* 1993; 11: 325-329.
- **Volm M, van Kaick G, Mattern J et al:** Analysis of c-fos, c-jun, c-erbB1, c-erbB2 and c-myc in primary lung carcinoma and their lymph node metastases. *Clin Exp Metastasis* 1994; 12: 329-334.
- **Volm M, Koomagi R, Mattern J, et al:** Prognostic value of p16INK4A expression in lung Adenocarcinoma. *Anticancer Res* 18: 3926, 1998.
- **Volm M, Koomagi R, Rittgen W:** Clinical implications of cyclins, cyclin dependent kinases, RB and E2F in squamous cell lung carcinoma. *Int J Cancer* 79:294, 1998.

W

- **Wanner A, Salathe M, Oriordan TG, et al:** Mucociliary clearance in the airways. *Am J Resp Crit Care Med* 1996; 154:1868.

- **Washimi O, Nagataka M, Oskada H, et al:** In vivo occurrence of p16 (MTS1) and p15 (MTS2) alternations preferentially in non-small cell lung cancers. *Cancer Res* 55:514, 1995.
- **Wei Q, Cheng L, Hong WK, et al:** Reduced DNA repair in lung cancer patients. *Cancer Res* 1996; 56:4103.
- **Wei Q, Spitz MR, Gu J, et al:** DNA repair capacity correlate with mutagen sensitivity in lymphoblastoid cell lines. *Cancer Epidemiol Biomarkers Prev* 1996; 5:199.
- **Wei MH, Latif F, Duh FM, et al:** Sequence analysis of a 700 kb DNA segment I 3p21.3 containing the putative small cell lung cancer gene: a window into a gene rich region of the human genome. *Proc Annu Meet Am Assoc Cancer Res* 38:A472, 1997.
- **Weidner N, Semple JP, Welch WR et al:** Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. *N Eng J Med* 1991; 324:1-8.
- **Weidner N, Carroll PR, Flax J et al:** Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. *Am J Pathol* 1993; 143: 401-409.
- **Weiss L:** Metastatic inefficiency. *Adv Cancer Res* 1990; 54:159-211.
- **Weiss SW, Nickoloff BJ:** CD34 is expressed by a distinctive cell population in peripheral nerve, nerve sheath tumors, and related lesions. *Am J Surg Pathol* 1993, 17: 1039-1045.
- **Westra WH, Slebos RJ, Offerhaus GJ, et al:** K-ras oncogene activation in lung Adenocarcinoma from former smokers. Evidence that k-ras mutations are an early and irreversible event in the development of Adenocarcinoma of the lung. *Cancer* 72:432, 1993.

- **Whaley JM, Naglich J, Gekbert L, et al:** Germ line mutations in the Von Hippel Lindau tumor suppressor gene are similar to somatic Von Hippel Lindau aberrations in sporadic renal cell carcinoma. *Am J Hum Genet* 55:1092, 1994.
- **Wick MR, Berg LC, Hertz MI:** Large cell carcinoma of lung with neuroendocrine differentiation. *Am J Clin Pathol* 1992; 97:796-805.
- **Wick MR, Ritter JH, Nappi O, et al:** Inflammatory sarcomatoid carcinoma of the lung. *Hum Pathol* 1995, 26: 1014-1021.
- **Wistuba II, Lam S, Behrens C, et al:** Molecular damage in the bronchial epithelium of current and former smokers. *J Natl Cancer Inst* 89: 1366, 1997.
- **Wu AH, Fontham ET, Reynelods P, et al:** Previous lung diseases and risk of lung cancer among lifetime non-smoking women. *Am J Epidemiol* 1995; 141:1023.

X

- **Xu ZY, Blot WJ, Xiao HP, et al:** Smoking, air pollution, and the high rates of lung cancer in Shenyang, China. *J Natl Cancer Inst* 1989; 81:1800.

Y

- **Yakubovskaya MS, Spiegelman v, Luo FC, et al:** High frequency of k-ras mutations in normal appearing lung tissues and sputum of patients with lung cancer. *Int J Cancer* 63:810, 1995.
- **Yamamura, Tsuyoshi, Nakanishi, et al:** Expression of membrane-type-1-matrix metalloproteinase and metalloproteinase-2 in non small cell lung cancer. *Lung cancer* 2002; 35(3): 249-55.
- **Yaman N, Mer S, Clehon O, et al:** Prognostic value of PCNA and silver-staining nucleolar organizer region (AgNOR) in renal cell

- carcinoma. Turkish Journal of cancer 1998, volume 28, number 2, page(s) 67-74.
- **Yamazaki K, Abe S, Takagawa H et al:** Tumor angiogenesis in human lung Adenocarcinoma. *Cancer* 1994, 74: 2245-2250.
 - **Yang HK, Linnoila RI, Conrad NK, et al:** P53 and RAS mutations in tumors from patients with cancer of the upper aerodigestive tract. *Int J Cancer* 64:229, 1995.
 - **Yang P, Wentzllaff KA, Karzman JA, et al:** Alpha-antitrypsin deficiency allele carriers among lung cancer patients. *Cancer Epidemiol Biomarkers Prev* 1999; 8:461.
 - **Yokota J, Yamamoto T, Toyoshima K et al:** Amplification of c-erbB2 in human Adenocarcinoma in vivo. *Lancet* 1986; 1: 765-767.
 - **Yousem SA, Hochholzer L:** Mucoepideroid tumors of the lung. *Cancer* 1987, 60: 1346-1352.
 - **Yuan Y, Yang PC, Lee YC et al:** Tumor angiogenesis correlate with histological type and metastasis in non-small cell lung cancer. *Am J Respir Crit Care Med* 1995, 152:2157-2162.

Z

- **Zaitoun AM:** Quantitative cytological assessment of Ki67 and AgNOR. *Cytopatholgy* 2000; 11: 243-254.
- **Zang EA, Wynder EL.** Difference in lung cancer risk between men and women; examination of the evidence. *J Natl Cancer Inst* 1996; 88:183.
- **Zhao T, Zhang YL, Li CD:** A comparison of proliferating cell nuclear antigen Immunostaining, nucleolar organizer region staining in lung cancer. *Chung-Hua-Chieh-Ho-Hu-His-Tsa-Chin* 1993 De: 16(6): 342-4,374.

References

- **Zheng W, Blot WJ, Liao ML, et al:** Lung cancer and prior tuberculosis infection in Shanghai. *Br J Cancer* 1987;56:510.
- **Zimonjic DB, Druck T, Ohta M, et al:** Positions of chromosome 3p14.2 fragile sites (FRA3B) within the FHIT gene. *Cancer Res* 57: 1166, 1997.